LIVIVO - Search results -

Search results

Result 1 - 10 of total 28

Search options

Article: The Pathophysiology and Management of Diabetic Ketoacidosis in COVID-19 Patients: a Literature Review.

Tilinca, Mariana Cornelia / Gliga, Maximilian Cosma / Varga, Andreea

Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures)

2021 Volume 8, Issue 1, Page(s) 6–13

Abstract: Diabetic individuals are considered a vulnerable population during the COVID-19 Pandemic, and several studies noted worse outcomes, including death, among those who get infected. Diabetic emergencies, such as ketoacidosis (DKA), are common and ... ...

Abstract	Diabetic individuals are considered a vulnerable population during the COVID-19 Pandemic, and several studies noted worse outcomes, including death, among those who get infected. Diabetic emergencies, such as ketoacidosis (DKA), are common and potentially life-threatening conditions in uncontrolled patients. While the pathophysiological background of the relationship between COVID-19 and DKA is not fully understood, early reports available so far indicate that patients with pre-existing diabetes who get infected with the SARS-CoV 2 virus are at higher risk of DKA. It was also suggested that DKA is a poor prognostic sign for infected patients, these being at higher risk of developing worse forms of COVID-19 disease and having high mortality. Therefore, healthcare personnel dealing with such patients face a considerable challenge, as the correct and safe emergency management of such cases is far from established. This article aimed to conduct a study that reviews the current published data available about patients with DKA and COVID-19.
Language	English
Publishing date	2021-11-13
Publishing country	Poland
Document type	Journal Article
ISSN	2393-1809
ISSN	2393-1809
DOI	10.2478/jccm-2021-0024
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients.

Tilinca, Mariana Cornelia / Tiuca, Robert Aurelian / Tilea, Ioan / Varga, Andreea

Journal of personalized medicine

2021 Volume 11, Issue 12

Abstract: Diabetes mellitus (DM) represents a major public health problem, with yearly increasing prevalence. DM is considered a progressive vascular disease that develops macro and microvascular complications, with a great impact on the quality of life of ... ...

Abstract	Diabetes mellitus (DM) represents a major public health problem, with yearly increasing prevalence. DM is considered a progressive vascular disease that develops macro and microvascular complications, with a great impact on the quality of life of diabetic patients. Over time, DM has become one of the most studied diseases; indeed, finding new pharmacological ways to control it is the main purpose of the research involved in this issue. Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are a modern drug class of glucose-lowering agents, whose use in DM patients has increased in the past few years. Besides the positive outcomes regarding glycemic control and cardiovascular protection in DM patients, SGLT-2i have also been associated with metabolic benefits, blood pressure reduction, and improved kidney function. The recent perception and understanding of SGLT-2i pathophysiological pathways place this class of drugs towards a particularized patient-centered approach, moving away from the well-known glycemic control strategy. SGLT-2i have been shown not only to reduce death from cardiovascular causes, but also to reduce the risk of stroke and heart failure hospitalization. This article aims to review and highlight the existing literature on the effects of SGLT-2i, emphasizing their role as oral antihyperglycemic agents in type 2 DM, with important cardiovascular and metabolic benefits.
Language	English
Publishing date	2021-11-25
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662248-8
ISSN	2075-4426
ISSN	2075-4426
DOI	10.3390/jpm11121249
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.

Tilinca, Mariana Cornelia / Tiuca, Robert Aurelian / Burlacu, Alexandru / Varga, Andreea

Medicina (Kaunas, Lithuania)

2021 Volume 57, Issue 7

Abstract: Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, ... ...

Abstract	Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term "diabesity" may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes.
MeSH term(s)	Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide 1 ; Glucagon-Like Peptide-1 Receptor ; Humans ; Hypoglycemic Agents/therapeutic use ; Liraglutide/therapeutic use
Chemical Substances	Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; Liraglutide (839I73S42A) ; Glucagon-Like Peptide 1 (89750-14-1)
Language	English
Publishing date	2021-06-29
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2188113-3
ISSN	1648-9144 ; 1010-660X
ISSN (online)	1648-9144
ISSN	1010-660X
DOI	10.3390/medicina57070669
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6270: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Delusional Parasitosis associated with diabetes mellitus treated in outpatient care during COVID-19 pandemic - case report].

Salcudean, Andreea / Bodo, Cristina Raluca / Tilinca, Mariana Cornelia / Strete, Elena Gabriela / Pacurar, Mariana / Károlyházy, Katalin / Márton, Krisztina

Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata

2022 Volume 37, Issue 1, Page(s) 52–59

Abstract: The presenile dermatozoic delusion, subsequently referred to as Ekbom's syndrome and delusional parasitosis is a rare chronic condition, having an undetermined etiology and rising challenging treatment approaches. The diagnosis of delusional parasitosis ... ...

Abstract	The presenile dermatozoic delusion, subsequently referred to as Ekbom's syndrome and delusional parasitosis is a rare chronic condition, having an undetermined etiology and rising challenging treatment approaches. The diagnosis of delusional parasitosis can be presumed on the basis of the clinical history, but it is important to thoroughly assess the existence of an underlying systemic disorder or unrecognized skin disorder. A skin examination must be performed to rule out an infestation or a skin disorder. We present a 63-year-old diabetic woman with a high level of resilience towards the psychiatric treatment for whom we successfully offered outpatient psychiatric and dermatological assistance during the pandemic COVID-19. The trigger for a successful treatment scheme in outpatient care in a case of delusional parasitosis was the close and trustful relationship between the patient and the doctor. Different pharmacological treatments were approached and adjusted according to the patient adherence and the objective result (quetiapine XR, duloxetine, risperidone, olanzapine, and lamotrigine along with chronic disease treatment and wound management). Having a mutual agreed objective criteria for the treatment outcome, and creating a throughout examination scheme with frequent medical checks, increased the patient adherence to the treatment.
MeSH term(s)	Ambulatory Care ; COVID-19 ; Delusional Parasitosis/diagnosis ; Delusional Parasitosis/drug therapy ; Diabetes Mellitus/diagnosis ; Diabetes Mellitus/therapy ; Female ; Humans ; Middle Aged ; Pandemics
Language	Hungarian
Publishing date	2022-03-11
Publishing country	Hungary
Document type	Case Reports ; Journal Article
ISSN	0237-7896
ISSN	0237-7896
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’

Mariana Cornelia Tilinca / Robert Aurelian Tiuca / Alexandru Burlacu / Andreea Varga

Medicina, Vol 57, Iss 669, p

A Narrative Review

2021 Volume 669

Abstract	Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term “diabesity” may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes.
Keywords	type 2 diabetes ; obesity ; GLP-1 RAs ; liraglutide ; diabesity ; Medicine (General) ; R5-920
Language	English
Publishing date	2021-06-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients

Mariana Cornelia Tilinca / Robert Aurelian Tiuca / Ioan Tilea / Andreea Varga

Journal of Personalized Medicine, Vol 11, Iss 1249, p

2021 Volume 1249

Abstract	Diabetes mellitus (DM) represents a major public health problem, with yearly increasing prevalence. DM is considered a progressive vascular disease that develops macro and microvascular complications, with a great impact on the quality of life of diabetic patients. Over time, DM has become one of the most studied diseases; indeed, finding new pharmacological ways to control it is the main purpose of the research involved in this issue. Sodium–glucose cotransporter 2 inhibitors (SGLT-2i) are a modern drug class of glucose-lowering agents, whose use in DM patients has increased in the past few years. Besides the positive outcomes regarding glycemic control and cardiovascular protection in DM patients, SGLT-2i have also been associated with metabolic benefits, blood pressure reduction, and improved kidney function. The recent perception and understanding of SGLT-2i pathophysiological pathways place this class of drugs towards a particularized patient-centered approach, moving away from the well-known glycemic control strategy. SGLT-2i have been shown not only to reduce death from cardiovascular causes, but also to reduce the risk of stroke and heart failure hospitalization. This article aims to review and highlight the existing literature on the effects of SGLT-2i, emphasizing their role as oral antihyperglycemic agents in type 2 DM, with important cardiovascular and metabolic benefits.
Keywords	diabetes mellitus ; SGLT-2 inhibitors ; antidiabetic agents ; cardiovascular outcomes ; personalized therapy ; Medicine ; R
Subject code	616
Language	English
Publishing date	2021-11-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Assessment of vitamin B12 levels and cardiovascular risk factors in metformin- and non-metformin-treated type 2 diabetic patients.

Ilona Nyulas, Kinga / Cornelia Tilinca, Mariana / Pál, Sándor / Fogarasi, Erzsébet Májai / Croitoru, Mircea Dumitru / Gabriel Tripon, Robert / Preg, Zoltán / Germán-Salló, Márta / Simon-Szabó, Zsuzsánna / Nemes-Nagy, Enikő

Pakistan journal of pharmaceutical sciences

2023 Volume 36, Issue 5, Page(s) 1399–1405

Abstract: Oxidative stress enhances cardiovascular risk. Metformin decreases intestinal absorption of vitamin B12. Our objective was the evaluation of type 2 diabetics focusing on differences due to their treatment. A prospective study on 224 type 2 diabetics was ... ...

Abstract	Oxidative stress enhances cardiovascular risk. Metformin decreases intestinal absorption of vitamin B12. Our objective was the evaluation of type 2 diabetics focusing on differences due to their treatment. A prospective study on 224 type 2 diabetics was realized between 2015-2018 in Targu Mures, Romania, divided into 2 subgroups (metformin vs. other therapy - 2
MeSH term(s)	Humans ; Metformin/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Cystatin C ; Diabetes Mellitus, Type 2 ; C-Reactive Protein ; Prospective Studies ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/chemically induced ; Risk Factors ; Vitamin B 12 ; Heart Disease Risk Factors ; Vitamins ; Homocysteine ; Zinc
Chemical Substances	Metformin (9100L32L2N) ; Hypoglycemic Agents ; Cystatin C ; C-Reactive Protein (9007-41-4) ; Vitamin B 12 (P6YC3EG204) ; Vitamins ; Homocysteine (0LVT1QZ0BA) ; Zinc (J41CSQ7QDS)
Language	English
Publishing date	2023-11-01
Publishing country	Pakistan
Document type	Journal Article
ZDB-ID	885131-1
ISSN	1011-601X
ISSN	1011-601X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6588: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review).

Tilinca, Mariana Cornelia / Tiuca, Robert Aurelian / Niculas, Cristina / Varga, Andreea / Tilea, Ioan

Experimental and therapeutic medicine

2021 Volume 22, Issue 4, Page(s) 1167

Abstract: Given their endemic prevalence in the past decades, obesity and type 2 diabetes mellitus (T2DM) have become a major sanitary burden with an important economic impact. Novel treatment options have been designed with the aim of reducing the numerous ... ...

Abstract	Given their endemic prevalence in the past decades, obesity and type 2 diabetes mellitus (T2DM) have become a major sanitary burden with an important economic impact. Novel treatment options have been designed with the aim of reducing the numerous complications associated with these metabolic disorders, as well as reducing morbidity and mortality and improving the quality of life of those who suffer from these disorders. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are among the most modern therapeutics that target 'diabesity', a term used to describe the pathophysiological link between obesity and T2DM. Their glucose-lowering effects are mainly attributed to glucose-dependent insulin secretion, glucagon inhibition and decreased gastric emptying. Given the effects on the central nervous system, GLP-1 RA usage may lead to body weight reduction. GLP-1 RAs are classified based on their pharmacokinetic properties as short- and long-acting agents, with both types being administered by subcutaneous injection. The latest agent from this drug class approved for use in T2DM is semaglutide, a long-acting compound that is the only GLP-1 RA available as an oral pill. The present narrative review highlights the most recently published data on the effects and safety of semaglutide in diabetic obesity, also emphasizing its cardiovascular benefits and potential side effects. In addition, an overview of the role of semaglutide in the treatment of non-diabetic obesity is provided.
Language	English
Publishing date	2021-08-12
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	2683844-8
ISSN	1792-1015 ; 1792-0981
ISSN (online)	1792-1015
ISSN	1792-0981
DOI	10.3892/etm.2021.10601
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The impact of body mass index on lipid profile, blood pressure, and glycemic control in patients with type 2 diabetes mellitus

Răuță Alina Elena / Tiucă Robert Aurelian / Trâmbițaș-Miron Alina Dia / Tilinca Mariana Cornelia

Acta Medica Marisiensis, Vol 67, Iss 1, Pp 16-

a comparative study

2021 Volume 22

Abstract: Objective: The aim of this study was to highlight the impact of body mass index on the lipid profile, blood pressure, and glycemic control in patients with type 2 diabetes mellitus. ...

Abstract	Objective: The aim of this study was to highlight the impact of body mass index on the lipid profile, blood pressure, and glycemic control in patients with type 2 diabetes mellitus.
Keywords	type 2 diabetes mellitus ; body mass index ; lipid profile ; blood pressure ; glucose control ; Medicine ; R
Language	English
Publishing date	2021-03-01T00:00:00Z
Publisher	Sciendo
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Evaluation of iron replacement therapy efficiency using a complex panel of biomarkers

Pál Sándor / Faust Zsuzsanna / Réger Barbara / Miseta Attila / Varjú-Solymár Margit / Nemes-Nagy Enikő / Tilinca Mariana Cornelia / Alizadeh Hussain

Romanian Journal of Laboratory Medicine, Vol 30, Iss 1, Pp 97-

2022 Volume 105

Keywords	Medicine ; R
Language	English
Publishing date	2022-01-01T00:00:00Z
Publisher	Sciendo
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED